Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouthwash interventions for early reduction of oral SARS-CoV-2 viral load in COVID-19
IRCT20170117032025N7Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules, Conventional Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of povidone-iodine, hydrogen peroxide, cetylpyridinium chloride and Normal Saline-Benha University in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Early reduction of viral load. Started Jul 2020; status: completed.
02
Drugs
povidone-iodinehydrogen peroxidecetylpyridinium chlorideNormal Saline-Benha University
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20170117032025N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170117032025N7.